SP5007,711.76-0.25%DOW53,559.99-0.02%NASDAQ26,402.42-0.52%BTC$77,728.00-3.40%ETH$2,441.16-2.91%GOLD$4,504.10-3.43%OIL$83.44-0.11%

NYSE · JNJ

Johnson & Johnson

Healthcare · Drug Manufacturers - General

$268.04

Up+$2.27 (+0.85%)

Updated Aug 31, 2026, 8:24 AM

SID Score

7.8/10

Composite research score

Smart Money

56/100

Neutral

Market cap: 505.78B
P/E ratio: 20.3
Dividend yield: 1.92%
52-week range: $199.91 – $276.47
Volume: 5.77M
Avg. volume: 8.82M

Price performance

JNJ price history

1M range · 20 trading sessions · Daily adjusted prices

Last close: $268.04
Period change: +5.36%
Period low: $254.41
Period high: $273.41

Daily close

View OHLC price history

JNJ OHLC price history, latest 40 sessions
Date	Open	High	Low	Close	Volume
Aug 28, 2026	$265.78	$268.38	$264.27	$268.04	5.77M
Aug 27, 2026	$268.45	$268.45	$263.83	$265.77	7.31M
Aug 26, 2026	$271.97	$272.905	$269.55	$270.00	7.22M
Aug 25, 2026	$271.00	$273.8021	$270.175	$273.14	4.69M
Aug 24, 2026	$269.74	$273.98	$268.57	$273.04	5.44M
Aug 21, 2026	$267.83	$272.655	$267.00	$270.24	6.19M
Aug 20, 2026	$273.40	$273.40	$267.37	$267.37	6.48M
Aug 19, 2026	$272.995	$276.47	$270.56	$273.41	7.73M
Aug 18, 2026	$267.67	$271.73	$266.33	$271.11	7.84M
Aug 17, 2026	$258.87	$264.2775	$258.01	$262.37	5.52M
Aug 14, 2026	$260.65	$261.71	$259.16	$260.35	5M
Aug 13, 2026	$261.725	$262.62	$259.6475	$262.08	4.85M
Aug 12, 2026	$256.00	$261.41	$255.255	$260.86	4.63M
Aug 11, 2026	$261.23	$264.15	$258.36	$259.80	5.95M
Aug 10, 2026	$259.06	$262.00	$258.55	$261.81	8.99M
Aug 7, 2026	$255.89	$259.60	$255.12	$259.24	6.53M
Aug 6, 2026	$261.71	$262.11	$255.28	$256.98	6.93M
Aug 5, 2026	$255.25	$259.32	$254.47	$257.59	6.47M
Aug 4, 2026	$254.41	$255.52	$250.44	$254.93	7.36M
Aug 3, 2026	$254.97	$257.75	$250.91	$254.41	8.14M

Latest JNJ news

The latest Smart Investors Daily articles mentioning JNJ.

Featured By

Inc.

Nasdaq

SID Score: 7.9/10
Fair value: $292.92
Generated: Aug 26, 2026
Model: claude-haiku-4-5-20251001

Executive Summary

Johnson & Johnson is trading at $273.14 with a market capitalization of $505.8 billion and demonstrates mixed investment signals. The company holds a SID Score of 7.9/10 with a fair value estimate of $292.92, suggesting 8.4% upside potential from current levels. However, the significant disconnect between the analyst consensus price target of $207.08 and current pricing raises questions about valuation alignment and market expectations.

Fundamental Analysis

JNJ's profitability receives a concerning C grade despite consistent earnings beats, with recent EPS results showing $2.9 (actual vs. $2.85 estimate) in July 2026 and $2.7 (actual vs. $2.67 estimate) in April 2026. The P/E ratio of 20.3x places the stock at a moderate valuation relative to historical norms, though the Value grade of D suggests limited margin of safety at current prices. The Growth grade of A indicates strong forward-looking prospects, while the Dividend grade of B is undermined by an exceptionally low 0.02% dividend yield, which is atypical for a company of JNJ's quality and size.

Technical Analysis

The stock is trading significantly above both its 50-day moving average of $255.52 and 200-day moving average of $239.08, reflecting an uptrend with 6.9% and 14.3% respective premiums. The RSI(14) reading of 73.3 indicates overbought conditions, suggesting potential near-term pullback risk despite the upward trajectory. Current price action presents a technical warning signal, as the extended RSI above 70 typically precedes consolidation or correction phases.

Analyst & Insider Sentiment

The analyst consensus rates JNJ as a "Buy," yet the average price target of $207.08 sits 24.2% below the current trading price, creating a substantial valuation contradiction. Recent insider activity shows mixed signals, with CEO Joaquin Duato executing a significant net sale of 254,991 shares (275,967 + 378,282 sold minus 399,258 bought) on August 13, 2026, which may suggest management's view of fair value relative to current levels. Additional insider selling by executive Elizabeth Forminard further compounds concerns about insider confidence at present valuations.

Risk Assessment

The primary risk is valuation compression, with the current price approximately $66 above the average analyst target, creating 24% downside exposure if consensus views materialize. Overbought technical conditions and insider selling patterns suggest near-term volatility, while the weak dividend yield of 0.02% fails to compensate for equity risk in a rising interest rate environment. The disconnect between fair value estimates ($292.92) and analyst targets ($207.08) indicates significant uncertainty in the investment community regarding JNJ's intrinsic worth.

Investment Thesis

JNJ presents a quality healthcare company with strong growth prospects and consistent earnings delivery, but current valuation offers limited margin of safety given the substantial gap between fair value and analyst consensus targets. The overbought technical condition, combined with recent insider selling and a substandard dividend yield, suggests waiting for a more opportune entry point rather than initiating positions at these levels. Conservative investors should consider accumulating JNJ during pullbacks toward the $255-$260 range, where the risk-reward profile becomes more attractive relative to the company's A-grade growth trajectory and proven operational execution.